NASDAQ:URGN Urogen Pharma (URGN) Stock Price, News & Analysis $19.44 -0.34 (-1.72%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$19.25 -0.19 (-1.00%) As of 08/22/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Urogen Pharma Stock (NASDAQ:URGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Urogen Pharma alerts:Sign Up Key Stats Today's Range$19.41▼$19.9950-Day Range$12.96▼$20.7252-Week Range$3.42▼$21.01Volume1.04 million shsAverage Volume1.06 million shsMarket Capitalization$899.29 millionP/E RatioN/ADividend YieldN/APrice Target$32.00Consensus RatingBuy Company Overview UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Read More Urogen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreURGN MarketRank™: Urogen Pharma scored higher than 91% of companies evaluated by MarketBeat, and ranked 104th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingUrogen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUrogen Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Urogen Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Urogen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Urogen Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.26% of the float of Urogen Pharma has been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 1.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.33 Percentage of Shares Shorted16.26% of the float of Urogen Pharma has been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 1.65%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.33 News SentimentUrogen Pharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Urogen Pharma this week, compared to 12 articles on an average week.Search InterestOnly 6 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows12 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $457,467.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Urogen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock News HeadlinesInsider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 5,149 Shares of StockJuly 31, 2025 | insidertrades.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21 at 8:00 AM | globenewswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 24 at 2:00 AM | Brownstone Research (Ad)Piper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comHC Wainwright Has Weak Outlook for Urogen Pharma Q3 EarningsAugust 16, 2025 | americanbankingnews.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? Urogen Pharma's stock was trading at $10.65 at the beginning of 2025. Since then, URGN shares have increased by 82.5% and is now trading at $19.44. How were Urogen Pharma's earnings last quarter? Urogen Pharma (NASDAQ:URGN) released its earnings results on Thursday, August, 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.23. The firm had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative trailing twelve-month return on equity of 97,487.15% and a negative net margin of 164.44%. Read the conference call transcript. When did Urogen Pharma IPO? Urogen Pharma (URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are Urogen Pharma's major shareholders? Top institutional investors of Urogen Pharma include Soleus Capital Management L.P. (4.72%), Acorn Capital Advisors LLC (2.72%), Menora Mivtachim Holdings LTD. (2.49%) and SG Americas Securities LLC (2.49%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith. View institutional ownership trends. How do I buy shares of Urogen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/07/2025Today8/24/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year Founded2004Price Target and Rating Average Price Target for Urogen Pharma$32.00 High Price Target$47.00 Low Price Target$16.00 Potential Upside/Downside+64.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.87 million Net Margins-164.44% Pretax Margin-160.04% Return on Equity-97,487.15% Return on Assets-59.38% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio3.99 Sales & Book Value Annual Sales$90.40 million Price / Sales9.95 Cash FlowN/A Price / Cash FlowN/A Book Value($2.02) per share Price / Book-9.62Miscellaneous Outstanding Shares46,260,000Free Float44,090,000Market Cap$899.29 million OptionableOptionable Beta1.12 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:URGN) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.